Feedback
Settings

Settings

Goto Application

805,908 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 80,591
1.WO/2026/101937COMPOSITIONS COMPRISING (Z)-ENDOXIFEN AND A CDK4/6 INHIBITOR AND METHODS OF USE THEREOF
WO - 15.05.2026
Int.Class A61K 31/138
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
 Appl.No PCT/US2025/054057 Applicant ATOSSA THERAPEUTICS, INC. Inventor QUAY, Steven Carl
The present disclosure relates to compositions and methods for treating hormone receptor positive (HR+) cancer with (Z)-endoxifen and a CDK4/6 inhibitor, such as abemaciclib. The disclosure is based on the discovery that (Z)-endoxifen and abemaciclib have synergistic effects on reducing tumor growth and proliferation in breast cancer models. The disclosure also provides fixed dose combinations of (Z)-endoxifen and abemaciclib, which offers advantages in terms of convenience and compliance. The compositions and methods are suitable for treating subjects with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer, especially those who are contraindicated for aromatase inhibitor therapy and/or ovarian suppression therapy.
2.WO/2026/102147TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS
WO - 15.05.2026
Int.Class C07D 417/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14containing three or more hetero rings
 Appl.No PCT/US2025/054404 Applicant TREELINE BIOSCIENCES, INC. Inventor HORN, Evan J.
protein. These compounds are useful, for example, for treating a cancer in a subject (e.g., a human). This disclosure also provides compositions comprising the compounds of Formula (I), (II), (III), (IV), (V), or (VI), or pharmaceutically acceptable salts thereof, provided herein as well as methods of using and making the same.
3.WO/2026/102297ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE
WO - 15.05.2026
Int.Class A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
 Appl.No PCT/US2025/054619 Applicant STUART, William Inventor STUART, William
Disclosed herein are antibody-oligonucleotide conjugates, pharmaceutical compositions, and methods for treating Sickle Cell Disease. The disclosure contemplates compositions and methods capable of binding a human hematopoietic stem cell marker conjugated to an oligonucleotide capable of hybridizing a target sequence. In some embodiments, the target sequence is a BCL11A transcript sequence. In some embodiments of the disclosure, the antibody-oligonucleotide conjugate promotes antisense- and/or RNA interference-mediated inhibition of BCL11A.
4.WO/2026/099477DOSING OF OLIGONUCLEOTIDE DRUGS FOR INHALATION
WO - 15.05.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/EP2025/082448 Applicant RNATICS GMBH Inventor RABE, Klaus F.
The present invention relates to a formulation comprising an oligonucleotide drug which is an antagonist of microRNA-21 as an active agent for administration to a human subject in need thereof by inhalation.
5.WO/2026/099597CANNIBIDIOL IN COMBINATION WITH CENOBAMATE FOR USE IN TREATING SEIZURES
WO - 15.05.2026
Int.Class A61K 31/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
 Appl.No PCT/GB2025/052445 Applicant JAZZ PHARMACEUTICALS RESEARCH UK LIMITED Inventor RANA, Rohini Rajyalaxmi
The present disclosure relates to methods for treating seizures in a subject in need thereof, more particularly to methods involving administration of a therapeutically effective amount of cannabidiol, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of cenobamate, or a pharmaceutically acceptable salt thereof. The disclosure also relates to said combination for use as a medicament for the treatment of seizures; and to kits comprising a pharmaceutical composition comprising cannabidiol, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising a cenobamate, or a pharmaceutically acceptable salt thereof.
6.WO/2026/100257TREATMENT OF MALIGNANT TUMOR
WO - 15.05.2026
Int.Class A61K 31/675
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
675having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
 Appl.No PCT/JP2025/034689 Applicant SYMBIO PHARMACEUTICALS LIMITED Inventor KAMITANI, Tetsu
Provided is a method for treating malignant tumor. Provided is a method for treating malignant tumor, the method comprising administering BCV, a pharmaceutically acceptable salt thereof, or a solvate of BCV or the pharmaceutically acceptable salt, and an immunotherapeutic agent to a subject. Alternatively, provided is a pharmaceutical composition for use in the treatment of malignant tumor, wherein the treatment comprises combination treatment to a subject with BCV, a pharmaceutically acceptable salt thereof, or a solvate of BCV or the pharmaceutically acceptable salt, and an immunotherapeutic agent, and wherein the pharmaceutical composition comprises BCV, a pharmaceutically acceptable salt thereof, or a solvate of BCV or the pharmaceutically acceptable salt, or an immunotherapeutic agent.
7.WO/2026/101232POLYMER COMPOUND FOR CELL SURFACE MODIFICATION FOR IMPROVING DRUG DELIVERY EFFICIENCY
WO - 15.05.2026
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
 Appl.No PCT/KR2025/018070 Applicant DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION Inventor KIM, Kyo Bum
The present invention relates to a polymer compound for cell surface modification for improving drug delivery efficiency. A polymer compound for natural killer cell surface modification according to an embodiment of the present invention includes a DSPE lipid having high hydrophobicity, and thus has the effect of increasing cell membrane immobilization efficiency and binding retention time. The polymer compound includes a prodrug at one end, and thus can improve the efficacy of immunotherapy through a target drug delivery system mediated by immune cells such as natural killer cells.
8.WO/2026/098802ULK1 INHIBITOR FOR THE TREATMENT OF A NEURODEGENERATIVE DISEASE
WO - 15.05.2026
Int.Class A61K 31/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
 Appl.No PCT/EP2025/070130 Applicant ETH ZÜRICH Inventor GEREZ, Juan Atilio
The invention relates to a ULK1 inhibitor for use in the treatment of a human or mammalian patient being diagnosed for, suffering from, or being at risk of developing a neurodegenerative disease, or in the prevention of such condition.
9.WO/2026/098592USE OF HETEROCYCLIC COMPOUND AND COMPLEX FORMED BY HETEROCYCLIC COMPOUND AND PHARMACEUTICALLY ACCEPTABLE ACID
WO - 15.05.2026
Int.Class A61K 31/4375
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4375the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
 Appl.No PCT/CN2025/133217 Applicant HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. Inventor ZHANG, Xuejun
The present invention relates to use of a heterocyclic compound and a complex formed by the heterocyclic compound and a pharmaceutically acceptable acid. Specifically, provided is use of a compound represented by formula (I-3B) or a complex thereof in the preparation of a drug for treating and/or preventing inflammatory bowel diseases. The complex is a complex formed by the compound represented by formula I-3B and a pharmaceutically acceptable acid. The compound represented by formula I-3B or the complex thereof can significantly mitigate IBD symptoms and tissue injury, and possesses good safety.
10.WO/2026/098607F-18 LABELED AQUEOUS PHARMACEUTICAL COMPOSITION TARGETING LIGAND OF FIBROBLAST ACTIVATION PROTEIN, AND PREPARATION METHOD THEREFOR
WO - 15.05.2026
Int.Class A61K 51/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier
04Organic compounds
 Appl.No PCT/CN2025/133289 Applicant TIANJIN HENGRUI MEDICINE CO., LTD. Inventor HAN, Jian
The present invention relates to an F-18 labeled aqueous pharmaceutical composition targeting a ligand of a fibroblast activation protein, and a preparation method therefor. Specifically, the present invention relates to an aqueous pharmaceutical composition of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The aqueous pharmaceutical composition possesses a high radiochemical purity.
# -